All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
with Paolo Gisondi, Andrew Alexis, and Mona Shahriari
Thursday, February 6, 2025
16:00-17:00 GMT
This independent educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Tacrolimus versus IV cyclophosphamide in patients with lupus nephritis
By Alice Hyde
Lupus nephritis (LN) is a common issue that patients with systemic lupus erythematosus (SLE) develop, with up to 60% of patients developing this sequela.1 For patients with SLE, LN development is associated with a significant level of morbidity and mortality; therefore, there is an urgent need to identify treatment combinations that combat this.1
A recent publication by Zheng et al.1 in Rheumatology investigated the effect of tacrolimus against intravenous cyclophosphamide in Chinese patients with LN. The Lupus Hub is happy to provide a visual abstract summarizing the data from this study.
- Zheng Z, Zhang H, Peng X, et al. Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: A randomized clinical trial. 2022;5(3):e224492. DOI: 10.1001/jamanetworkopen.2022.4492
Related articles
Newsletter
Subscribe to get the best content related to lupus delivered to your inbox